| 1997-03 |
BioMarin was founded in Novato, California, with an initial focus on leveraging its proprietary enzyme technology to develop therapies for genetic conditions and other diseases. |
| 1997-12 |
BioMarin initiated its first clinical trial to evaluate a potential treatment a form of mucopolysaccharidosis. |
| 1999-07 |
BioMarin completed its initial public offering. Since a large number of early investors were based in Europe, the company was listed on both the Swiss SWX Exchange and the Nasdaq National Market. |
| 2003-04 |
The FDA granted marketing authorization for BioMarin’s enzyme replacement therapy for the treatment of a form of mucopolysaccharidosis. The medicine was approved in Europe that June. |
| 2005-05 |
BioMarin’s Board of Directors elected Jean-Jacques Bienaimé as the company’s Chief Executive Officer, a role he would hold for more than 18 years. |
| 2005-05 |
The FDA approved BioMarin’s first independently developed and commercialized medicine, and the first authorized treatment for a second form of mucopolysaccharidosis. |
| 2006 |
The company established BioMarin Europe Ltd., headquartered in London, initially with offices in Spain, Switzerland and Italy. The company now operates in more than 70 countries around the world. |
| 2007-12 |
The FDA approved the first therapy for the treatment of a rare metabolic condition. |
| 2011 |
The company completed the purchase of a manufacturing facility in Shanbally, Ireland, and in November, the FDA approved the expansion of BioMarin’s biologics manufacturing facility in Novato, California. |
| 2013-02 |
BioMarin announced it had licensed the program from University College London and St. Jude Children’s Research Hospital. This would lead to a product approval approximately 10 years later. |
| 2014-02 |
The FDA approved BioMarin’s therapy for the treatment of another form of mucopolysaccharidosis. |
| 2016 |
Expanding on its decade-long track record of supporting eligible people with rare diseases in gaining access to the company’s medicines, the BioMarin RareConnections program consolidated these efforts under one expanded program for people in the United States. |
| 2017-04 |
The FDA approved BioMarin’s medicine for the treatment of an ultra-rare form of Batten disease. |
| 2018-05 |
The FDA approved the first enzyme replacement therapy to target the underlying cause of a rare metabolic condition. |
| 2021-11 |
Therapy for a Form of Skeletal Dysplasia Approved |
| 2022-08 |
The European Commission approved BioMarin’s first gene therapy for the treatment of an inheritable bleeding disorder. |
| 2023-06 |
The FDA approved BioMarin’s gene therapy for the treatment of an inheritable bleeding disorder. |
| 2023-12 |
With the retirement of longtime BioMarin CEO Jean-Jacques Bienaimé, Alexander Hardy was named President and Chief Executive Officer. |
| 2024-07 |
The expanded indication included children of all ages living with the ultra-rare form of Batten disease, enabling even younger children to receive the only available treatment for this debilitating and ultimately fatal condition. |
| 2025-07 |
The acquisition strengthened BioMarin’s enzyme therapies portfolio, adding a late-stage investigational enzyme replacement therapy for ENPP1 deficiency. |
| 2026-02 |
The FDA approved BioMarin’s supplemental Biologics License Application to include people 12 years of age and older living with a rare metabolic condition. |
| 2026-04 |
The acquisition added two new treatments for rare lysosomal storage diseases to the company’s commercial portfolio, opening up more possibilities for people living with the conditions around the world to access therapy due to BioMarin’s global footprint. |
